Anitsense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $17.5M Series E financing. Participants include MIG Fonds and Global Asset Fund.